Raloxifene is an oral selective estrogen receptor modulator which is used in the prevention of osteoporosis in postmenopausal women. It was announced on April 17, 2006, that raloxifene is as effective as tamoxifen in reducing the incidence of breast cancer in certain high risk groups of females, [http://ca.today.reuters.com/news/newsArticle.aspx?type=topNews&storyID=2006-04-18T001012Z_01_N17276340_RTRIDST_0_NEWS-CANCER-BREAST-COL.XML&archived=False though with a reduced risk of thromboembolic events and cataracts in patients taking raloxifene versus those taking tamoxifen. It has not been approved by the FDA for this use, and there has been criticism in the mainstream oncology press of the way that the information was released ( A STARring role for raloxifene? Lancet Oncology 7 (6) Page 443 please wikify). There has been some confusion in the lay media about the meaning of the trial results. There is no specific clinical evidence for the use of Raloxifene in the adjuvant treatment of breast cancer over established drugs such as Tamoxifen or Anastrozole.
Raloxifene is produced by Eli Lilly Pharmaceuticals and is sold under the brand name Evista.
SERMs mimic estrogen in some tissues and have anti-estrogen activity in others. Other SERMs, such as Pfizer's lasofoxifene and Wyeth's bazedoxifene are in the late stages of clinical development.
More on [ Raloxifene ]

DrugDigest: Raloxifene ( Evista ) - Information on dosage, usage, side effects, interactions, and drug comparisons, including generics when available.
Evista - Features product information, support program, osteoporosis resources, risk factors, and FAQs.
Meta Description: [ Eli Lilly provides information for patients on the prevention and treatment of osteoporosis with Evista. Here you can find practical tools and strategies for preventing osteoporosis and living a healthy life if you have been diagnosed with this disease. ]
MEDLINEplus: Raloxifene - Information about the use and side effects of this medication.
Meta Description: [ Raloxifene(Systemic) ]
Raloxifene Halves Cerebrovascular Risk in Postmenopausal Women - Report on results of the Multiple Outcomes of Raloxifene Evaluation trial. [Free registration required.]
Raloxifene: A Selective Estrogen Receptor Modulator - Discusses the drug and its use in the treatment of osteoporosis.
| Osteoporosis drug is approved for prevention of breast cance | |